Xcout Intel
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. was a San Diego-based clinical-stage biotechnology company developing treatments for serious and potentially life-threatening fungal infections. Its lead investigational drug, fosmanogepix, was acquired by Pfizer when Pfizer acquired Amplyx in 2021 and is being developed for patients with invasive fungal diseases.
Subscribe to see Amplyx Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Amplyx Pharmaceuticals, Inc. at a glance
Amplyx Pharmaceuticals, Inc. is a biopharma company headquartered in United States. Its most recent funding round raised $81.5M in April 2021.
Amplyx Pharmaceuticals, Inc. funding rounds
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $81.5M | 13 named | |
| SEC Form D filing | $91.3M | — | |
| Series C | $91.3M | 12 named | |
| SEC Form D filing | $23.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Amplyx Pharmaceuticals, Inc. competitors
A few of Amplyx Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Pulmocide is a UK drug-discovery and development company focused on inhaled treatments for serious fungal lung infections. Its lead candidate, opelconazole (PC945), is an inhaled antifungal being developed for pulmonary aspergillosis and related respiratory fungal diseases, serving patients with difficult-to-treat pulmonary infections.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Founded in 2021 and headquartered in Shenzhen, China, MagicRNA Biotechnology Co., Ltd. is a clinical-stage biotechnology company focused on nucleic acid drug delivery and the research and development of next-generation mRNA and lipid nanoparticle technologies for the treatment of cancer and infectious diseases.
OncoMyx Therapeutics, Inc. is a biotechnology company headquartered in Phoenix, Arizona, that develops innovative oncolytic immunotherapies to target and destroy tumors.
Get Amplyx Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Amplyx Pharmaceuticals, Inc. in Xcout Intel
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access